Syntis Bio appoints Matthew Dallas as Chief Financial Officer

pharmafile | August 3, 2026 | Appointment | |  Syntis Bio 

Syntis Bio has appointed Matthew Dallas as Chief Financial Officer (CFO). Dallas brings more than 25 years of financial expertise and management experience in the life sciences industry.

Dallas most recently served as CFO of Pulmocide, where he oversaw all aspects of the company’s capital strategy, finance and investor relations functions. Prior to that, he was CFO of Zealand Pharma, a Danish biotechnology research company that designs and develops peptide-based medicines mainly focusing on metabolic diseases, like diabetes and obesity. He also previously held CFO roles with AVEO Oncology and CoLucid Pharmaceuticals.

Rahul Dhanda, CEO of Syntis Bio, commented: “Matt has navigated the full arc of building a biopharmaceutical company – from public and private financing strategies to scaling operations to forging partnerships. He will be a tremendous asset as we build our financial foundation and look towards our next phase of growth and long-term success.”

Advertisement

Dallas said: “I look forward to working closely with Rahul and the leadership team to scale our business and support it through financial strategies that translate into significant value creation while delivering new therapies to patients who need them.”

Syntis Bio is a clinical-stage biopharmaceutical company with a growing pipeline across obesity and rare disease.

Related Content

No items found
The Gateway to Local Adoption Series

Latest content